Search Results

The Codman Certas Plus Programmable Valve is an implantable device that provides constant intraventricular pressure and drainage of CSF for the management of hydrocephalus.

This submission includes two additional configurations of the Codman Certas Plus Programmable Valve: Certas Plus Inline Small and Certas Plus Right Angle. The Codman Certas Plus Programmable Valves are sterile, single use, implantable devices designed for shunting cerebrospinal fluid (CSF) for the treatment of hydrocephalus.

The Codman Certas Plus Programmable Valve is a pressure-regulating valve utilizing the ruby ball-in-cone principle with a pressure inducing spring design. Intraventricular pressure is maintained by the ball and cone valve seat design. As the differential pressure across the shunt increases, the ball further displaces from the cone, through which CSF flows, thereby increasing flow and re-establishing the selected pressure. The ball is manufactured of synthetic ruby, as is the matching cone. Together these components provide a precise fit for regulating the flow of CSF through the valve.

The valve is available with 8 different performance settings for constant intraventricular pressure and drainage of CSF. Seven (7) of the settings provide a change in operating pressure, with a range of 25 to 215 mmH2O. The eighth (8) setting provides a minimum opening pressure of '400' mmH20, thus allowing a physician to turn the valve "virtually off" without the need to surgically remove the valve to limit flow. The pressure of the valve is set preoperatively and can be noninvasively changed postimplantation by using the Codman Certas Tool Kit.

The provided document is a 510(k) premarket notification for a medical device, specifically the Codman Certas Plus Programmable Valve. This type of submission is for demonstrating substantial equivalence to a predicate device, not for proving the device meets acceptance criteria through an AI-based study or a multi-reader, multi-case (MRMC) comparative effectiveness study. The document primarily focuses on bench testing (Verification Testing) and simulated use (Validation Testing) to establish that the modified versions of the device perform equivalently to the predicate.

Therefore, many of the questions related to AI-specific study design (like ground truth establishment, expert consensus, MRMC studies, training/test set sizes, and specific performance metrics like AUC, sensitivity, specificity for diagnostic AI) are not applicable to this document.

However, I can extract information related to the physical device's performance, acceptance criteria for those tests, and the general approach to validating the device's functionality.

Here's a breakdown of the requested information based on the provided document:

Acceptance Criteria and Device Performance for Codman Certas Plus Programmable Valve

The device is a non-AI, physical medical device (a CSF shunt) and therefore the typical "acceptance criteria" and "study" described in an AI context (e.g., AUC, sensitivity, specificity, MRMC studies) are not present. Instead, the document describes design verification and validation activities against established standards and internal criteria to demonstrate substantial equivalence to a predicate device.

1. A table of acceptance criteria and the reported device performance

The document states that "All samples in design verification testing met predefined acceptance criteria" and "test results demonstrated that the acceptance criteria were met." However, the specific numerical acceptance criteria for each test are not explicitly detailed in this summary. The results are reported as "PASS."

2. Sample sizes used for the test set and the data provenance

The document does not specify the exact sample sizes (number of units tested) for each verification and validation test. It generally refers to "all samples" meeting criteria. This is typical for 510(k) summaries where the detailed test protocols and sample sizes are provided in the full submission, but not always summarized in this public document.

Data provenance: The testing was conducted by Integra LifeSciences Production Corp. (manufacturer/applicant). The document doesn't explicitly state the country of origin of the data in terms of patient source, as this is bench and simulation testing, not clinical data from patients. The testing is retrospective in the sense that it's performed on manufactured devices, not derived from real-time patient observations.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This question is not applicable. For a physical device like a shunt, "ground truth" generally refers to the known physical properties and performance specifications, established through engineering and quality control benchmarks, and adherence to international standards (e.g., ISO). For the "System Safety Study" (validation), "clinicians" were involved, but their number and specific qualifications are not detailed. Their role was to evaluate the device in simulated use.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. This concept is relevant for studies involving human interpretation of data, typically in diagnostic imaging or AI performance assessment. For physical device performance, reconciliation/adjudication is typically handled by senior engineers or quality assurance personnel reviewing failed tests, not by a formal multi-reader adjudication process.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is a physical medical device, not an AI diagnostic or assistance system. The "System Safety Study" involved clinicians but was a usability/performance study in a simulated environment, not an MRMC study.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This is not an algorithm. The device functions mechanically.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)

The "ground truth" for this device's performance is based on:

• Adherence to international standards (e.g., ISO 7197:2009, ISO 17665-1: 2006, ISO 17665-2: 2009, ISO 11067-1: 2009, ISO11607-2: 2006, ISTA 3A).
• Predefined engineering specifications and performance characteristics (e.g., pressure-flow characteristics, strength, sterilization effectiveness).
• Comparison to the performance of the legally marketed predicate device (K152152) and reference device (K053107) to demonstrate substantial equivalence.

8. The sample size for the training set

Not applicable. This is a physical device, not an AI model requiring a training set.

9. How the ground truth for the training set was established

Not applicable.

Ask a specific question about this device

The Codman Certas Plus Programmable Valve is an implantable device that provides constant intraventricular pressure and drainage of CSF for the management of hydrocephalus.

The Codman Certas Plus Programmable Valve is a sterile, single use, implantable device designed for shunting cerebrospinal fluid (CSF) for the treatment of hydrocephalus.

The Codman Certas Plus Programmable Valve is a pressure-regulating valve utilizing the ruby ball-in-cone principle with a pressure inducing spring design. Intraventricular pressure is maintained by the ball and cone valve seat design. As the differential pressure across the shunt increases, the ball further displaces from the cone, through which CSF flows, thereby increasing flow and re-establishing the selected pressure. The ball is manufactured of synthetic ruby, as is the matching cone. Together these components provide a precise fit for regulating the flow of CSF through the valve.

The valve is available with 8 different performance settings for constant intraventricular pressure and drainage of CSF. Seven (7) of the settings provide for a change in operating pressure, with a range of 25 to 215 mmH2O. The eighth setting provides a minimum opening pressure of '400' mmH20, thus allowing a physician to turn the valve "virtually off" without the need to surgically remove the valve to limit flow. The pressure of the valve is set preoperatively and can be noninvasively changed post-implantation by using the Codman Certas Tool Kit, which employs magnetic force to select one of the 8 settings.

The provided text describes a 510(k) premarket notification for the Codman Certas Plus Programmable Valve, where the manufacturer is seeking to expand its indications for use to include ventriculo-atrial (VA) shunting. The key focus of the submission is to demonstrate substantial equivalence to a predicate device for this expanded use.

Here's an analysis of the acceptance criteria and the study that proves the device meets them, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Sizes Used for the Test Set and Data Provenance

• Bench Testing: The document does not specify the exact sample sizes used for reflux testing or shelf-life testing.
• Data Provenance: The data comes from internal testing conducted by Codman, the device manufacturer. It is prospective testing, performed specifically to support this 510(k) submission for expanded indications. The country of origin of the data is not explicitly stated, but the submitter is Codman & Shurtleff, Inc., based in Raynham, MA, USA, and Medos International SARL in Le Locle, Switzerland.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications

• No external experts were used to establish ground truth for the bench testing. The "ground truth" for these tests is defined by the international standards (ISO and ASTM) and internal company specifications for performance.

4. Adjudication Method for the Test Set

• No adjudication method is described as the testing performed was objective bench testing against pre-defined standards.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

• No MRMC comparative effectiveness study was done. This filing is for a physical medical device (a programmable valve) and not an AI/imaging diagnostic device.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

• Not applicable. This is not an AI algorithm.

7. The Type of Ground Truth Used

• For bench testing, the ground truth is defined by international consensus standards (ISO 7197:2009, ASTM F647:1994 (R2006)) and internal company specifications that ensure the device meets predefined performance characteristics (e.g., reflux limits, shelf life stability).
• For biocompatibility, the ground truth is based on regulatory and scientific standards (ISO 10993-1, ISO 10993-4) and FDA guidance, often relying on established material safety data.

8. The Sample Size for the Training Set

• Not applicable. This is not a machine learning or AI device that requires a training set. The device itself is the product under review.

9. How the Ground Truth for the Training Set Was Established

• Not applicable, as there is no training set for this device.

Ask a specific question about this device

The Codman Certas Plus Programmable Valve is an implantable device that provides constant intraventricular pressure and drainage of CSF for the management of hydrocephalus.

The Codman Certas Tool Kit allows the noninvasive reading or adjustment of the valve setting.

The Codman Certas Plus Programmable Valve is a sterile, single use, implantable device designed for shunting cerebrospinal fluid (CSF) for the treatment of hydrocephalus.

The Codman Certas Plus Programmable Valves are pressure-regulating valves utilizing the ruby ball-in-cone principle with a pressure inducing spring design. Intraventricular pressure is maintained by the ball and cone valve seat design. As the differential pressure across the shunt increases, the ball further displaces from the cone, through which CSF flows, thereby increasing flow and re-establishing the selected pressure. The ball is manufactured of synthetic ruby, as is the matching cone. Together these components provide a precise fit for regulating the flow of CSF through the valve.

The valve is available with 8 different performance settings for constant intraventricular pressure and drainage of CSF. Seven (7) of the settings provide for a change in operating pressure, with a range of 25 to 215 mmH2O. The eighth setting provides a minimum opening pressure of '400' mmH20, thus allowing a physician to turn the valve “virtually off” without the need to surgically remove the valve to limit flow. The pressure of the valve is set preoperatively and can be noninvasively changed post-implantation by using the Codman Certas Tool Kit, which employs magnetic force to select one of the 8 settings.

The provided text does not contain information related to the acceptance criteria and study details for an AI/ML-based device. The document is a 510(k) premarket notification for a medical device (Codman Certas Plus Programmable Valve and Codman Certas Tool Kit), which is a physical implantable device and its accompanying tool kit, not a software or AI/ML algorithm.

Therefore, the specific questions regarding AI/ML performance metrics, sample sizes for AI/ML models, expert qualifications for ground truth, adjudication methods, MRMC studies, or standalone algorithm performance are not applicable to this document.

The document discusses various forms of bench testing, MRI testing, and biocompatibility testing for the physical device, and states that no animal or clinical studies were required due to the device's similarity to a predicate device and successful bench testing.

There is no information in the provided text that allows for the completion of the requested table and answers related to AI/ML device criteria.

Ask a specific question about this device